Banco Santander (SAN) 7.18 $SAN
Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network's WORLD Symposium 2015
Business Wire - Thu Feb 12, 3:15PM CST
Genzyme, a Sanofi company, today presented data from its Phase 1b clinical study at the Lysosomal Disease Network's WORLD Symposium 2015 in Orlando, Fla. detailing the investigational use of enzyme replacement therapy in the non-neurological manifestations of acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease type
, a lysosomal storage disease caused by genetic mutations that affect the metabolism of sphingomyelin. The Genzyme study evaluated the tolerability and safety of olipudase alfa (recombinant human acid sphingomyelinase) in five adult patients with ASMD.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
26.3% Return Seen to Date on SmarTrend Banco Santander Call (SAN)
Comtex SmarTrend(R) - Thu Feb 12, 11:04AM CST
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 5 months, Banco Santander has returned 26.26% as of today's recent price of $6.98.
SAN: 7.18 (+0.13)
Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga(R) (eliglustat) at Lysosomal Disease Network's WORLD Symposium 2015
Business Wire - Thu Feb 12, 7:45AM CST
Genzyme, a Sanofi company, today reported extension study data from its Phase 3 ENGAGE and ENCORE studies of Cerdelga(R) (eliglustat), a first-line oral therapy approved by the FDA and the European Commission for the treatment of certain adults with Gaucher disease type 1. The results from the studies were presented today at the 11th Annual Lysosomal Disease Network WORLD Symposium in Orlando, Fla. Both extension studies demonstrated continued stability and/or improvements across established end points and published therapeutic treatment goals.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
HSBC Admits Aiding Tax Evasion by Clients at Swiss Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 1:28PM CST
In response to media reports that accused HSBC of aiding wealthy customers to evade taxes, the company issued a statement saying, "We acknowledge and are accountable for past compliance and control failures."
SAN: 7.18 (+0.13), BCA: 18.35 (+0.49), HSBC: 46.13 (-0.01), GGAL: 18.98 (+0.93)
HSBC Remains Firmly on Top of SNL Financial's European Bank Market Capitalization Ranking
PRWeb - Sun Feb 08, 6:00PM CST
HSBC Holdings Plc, Banco Santander SA, Lloyds Banking Group Plc and BNP Paribas SA remained in the top four places in SNL Financial's new league table of Europe's 20 largest banks by market capitalization.
SAN: 7.18 (+0.13), HSBC: 46.13 (-0.01)
Downtrend Call Working As Banco Santander Stock Falls 26.8% (SAN)
Comtex SmarTrend(R) - Thu Feb 05, 9:41AM CST
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 4 months, Banco Santander has returned 26.82% as of today's recent price of $6.93.
SAN: 7.18 (+0.13)
Sanofi Delivers Business EPS Growth of 7.3% at CER in 2014
PR Newswire - Thu Feb 05, 6:49AM CST
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
Banco Santander, S.A.'s (SAN) CEO Jose Antonio Alvarez on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 1:40PM CST
SAN: 7.18 (+0.13)
Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
PR Newswire - Tue Feb 03, 6:00AM CST
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes.
SAN: 7.18 (+0.13), MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Wall Street Breakfast: Australia Next To Fly With The Doves
Wall Street Breakfast - at Seeking Alpha - Tue Feb 03, 5:35AM CST
SPLS: 16.86 (-0.22), SD: 2.09 (+0.14), AMZN: 381.83 (+4.66), GE: 25.15 (+0.26), INVN: 16.08 (+0.09), SNE: 27.30 (+0.19), RSH: 0.24 (-0.04), MHFI: 102.19 (unch), GOOG: 549.01 (+6.08), MCO: 98.22 (+0.01), RSYS: 2.15 (+0.05), T: 34.66 (+0.05), SAN: 7.18 (+0.13), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), IDT: 22.38 (+0.02), S: 5.23 (+0.08), PLCE: 59.21 (+0.02), ODP: 9.59 (-0.02), BP: 41.93 (+0.59), GOOGL: 551.16 (+5.15), VZ: 49.31 (-0.21), BABA: 89.05 (+1.95)
Santander lifted by heavy profit
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 5:23AM CST
SAN: 7.18 (+0.13)
European Stocks Rise as Greek Government Backs Down From Debt Cut Request
at The Street - Tue Feb 03, 5:22AM CST
European stocks rise Tuesday as the new Greek government looks to be backing down from a confrontation with euro-area leaders over a debt write-down.
SAN: 7.18 (+0.13), BHP: 51.19 (+2.38), BP: 41.93 (+0.59)
Why This Big Bank Slashed Its High-Yield Dividend
Eric Volkman, The Motley Fool - Motley Fool - Wed Jan 28, 9:32AM CST
Two words no investor ever wants to hear are "dividend cut." That's especially true when the cutter reduces its payout by two-thirds in one fell swoop. That's what happened earlier this month when sprawling Europe-based financial group Banco...
SAN: 7.18 (+0.13), C: 51.20 (+0.31)
Regeneron and Sanofi Announce Praluent(TM) (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
PR Newswire - Mon Jan 26, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for PraluentTM (alirocumab). Under the Prescription Drug User Fee Act (PDUFA), the goal for a priority review is six months, for a target action date of July 24, 2015. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
GE Q4 Operating Earnings Beat on Sustained Industrial Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 9:13AM CST
Sustained focus on core industrial business enabled General Electric Company (GE) to report strong fourth quarter 2014 results, with solid industrial segment profit growth and margin expansion.
SAN: 7.18 (+0.13), GE: 25.15 (+0.26), FSS: 15.75 (+0.09)
There's A Lot Of Value In The Information Technology Sector: The S&P 500 2015: Part 3
Chuck Carnevale - at Seeking Alpha - Thu Jan 22, 1:56PM CST
FB: 75.74 (-0.49), STX: 61.83 (+0.67), GOOG: 549.01 (+6.08), HPQ: 38.56 (+0.19), SAN: 7.18 (+0.13), FSLR: 48.84 (-0.58), IOT: 6.43 (+0.05), QCOM: 70.88 (+0.49), EMC: 27.99 (+0.12), GOOGL: 551.16 (+5.15), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03), MA: 87.14 (-0.38)
Spain: Unemployment stuck at 23.7 percent in Q4
AP - Thu Jan 22, 10:28AM CST
MADRID (AP) — Spain's unemployment rate remained stuck at 23.7 percent in the fourth quarter ending in December compared with the previous three-month period, marking an end to a series of joblessness rate declines throughout 2014, the government's statistics agency said Thursday.
SAN: 7.18 (+0.13), SANW: 4.80 (+0.19)
Santander Holdings announces preferred stock dividend of USD0.45625 per depositary share
M2 - Thu Jan 22, 3:11AM CST
Santander Holdings USA Inc, the parent company of Santander Bank NA (NYSE:SAN), reported on Wednesday that its board of directors authorised a dividend of USD0.45625 per depositary share on its series C non-cumulative perpetual preferred stock (NYSE:SOVPRC).
SAN: 7.18 (+0.13)
European Commission Grants Marketing Authorization for Cerdelga(R) (eliglustat), Genzyme's Oral Therapy for Gaucher Disease Type 1
Business Wire - Thu Jan 22, 12:00AM CST
Genzyme, a Sanofi company, announced today that the European Commission (EC) has granted marketing authorization for Cerdelga(R) (INN: eliglustat) capsules, a first line oral therapy for certain adults living with Gaucher disease type 1. A small number of adult patients who metabolize Cerdelga more quickly or at an undetermined rate, as detected by an established genetic laboratory test, will not be eligible for Cerdelga treatment. Cerdelga was approved by the U.S. Food and Drug Administration in August 2014, and is under review by other regulatory authorities around the world. It is expected that Cerdelga will be available commercially in EU countries beginning in 2015 and over the next few years.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network's WORLD Symposium 2015
Business Wire - Thu Feb 12, 3:15PM CST
Genzyme, a Sanofi company, today presented data from its Phase 1b clinical study at the Lysosomal Disease Network's WORLD Symposium 2015 in Orlando, Fla. detailing the investigational use of enzyme replacement therapy in the non-neurological manifestations of acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease type
, a lysosomal storage disease caused by genetic mutations that affect the metabolism of sphingomyelin. The Genzyme study evaluated the tolerability and safety of olipudase alfa (recombinant human acid sphingomyelinase) in five adult patients with ASMD. SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
26.3% Return Seen to Date on SmarTrend Banco Santander Call (SAN)
Comtex SmarTrend(R) - Thu Feb 12, 11:04AM CST
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 5 months, Banco Santander has returned 26.26% as of today's recent price of $6.98.
SAN: 7.18 (+0.13)
Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga(R) (eliglustat) at Lysosomal Disease Network's WORLD Symposium 2015
Business Wire - Thu Feb 12, 7:45AM CST
Genzyme, a Sanofi company, today reported extension study data from its Phase 3 ENGAGE and ENCORE studies of Cerdelga(R) (eliglustat), a first-line oral therapy approved by the FDA and the European Commission for the treatment of certain adults with Gaucher disease type 1. The results from the studies were presented today at the 11th Annual Lysosomal Disease Network WORLD Symposium in Orlando, Fla. Both extension studies demonstrated continued stability and/or improvements across established end points and published therapeutic treatment goals.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
HSBC Admits Aiding Tax Evasion by Clients at Swiss Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 1:28PM CST
In response to media reports that accused HSBC of aiding wealthy customers to evade taxes, the company issued a statement saying, "We acknowledge and are accountable for past compliance and control failures."
SAN: 7.18 (+0.13), BCA: 18.35 (+0.49), HSBC: 46.13 (-0.01), GGAL: 18.98 (+0.93)
HSBC Remains Firmly on Top of SNL Financial's European Bank Market Capitalization Ranking
PRWeb - Sun Feb 08, 6:00PM CST
HSBC Holdings Plc, Banco Santander SA, Lloyds Banking Group Plc and BNP Paribas SA remained in the top four places in SNL Financial's new league table of Europe's 20 largest banks by market capitalization.
SAN: 7.18 (+0.13), HSBC: 46.13 (-0.01)
Downtrend Call Working As Banco Santander Stock Falls 26.8% (SAN)
Comtex SmarTrend(R) - Thu Feb 05, 9:41AM CST
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 4 months, Banco Santander has returned 26.82% as of today's recent price of $6.93.
SAN: 7.18 (+0.13)
Sanofi Delivers Business EPS Growth of 7.3% at CER in 2014
PR Newswire - Thu Feb 05, 6:49AM CST
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
Banco Santander, S.A.'s (SAN) CEO Jose Antonio Alvarez on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 1:40PM CST
SAN: 7.18 (+0.13)
Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
PR Newswire - Tue Feb 03, 6:00AM CST
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes.
SAN: 7.18 (+0.13), MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Wall Street Breakfast: Australia Next To Fly With The Doves
Wall Street Breakfast - at Seeking Alpha - Tue Feb 03, 5:35AM CST
SPLS: 16.86 (-0.22), SD: 2.09 (+0.14), AMZN: 381.83 (+4.66), GE: 25.15 (+0.26), INVN: 16.08 (+0.09), SNE: 27.30 (+0.19), RSH: 0.24 (-0.04), MHFI: 102.19 (unch), GOOG: 549.01 (+6.08), MCO: 98.22 (+0.01), RSYS: 2.15 (+0.05), T: 34.66 (+0.05), SAN: 7.18 (+0.13), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), IDT: 22.38 (+0.02), S: 5.23 (+0.08), PLCE: 59.21 (+0.02), ODP: 9.59 (-0.02), BP: 41.93 (+0.59), GOOGL: 551.16 (+5.15), VZ: 49.31 (-0.21), BABA: 89.05 (+1.95)
Santander lifted by heavy profit
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 5:23AM CST
SAN: 7.18 (+0.13)
European Stocks Rise as Greek Government Backs Down From Debt Cut Request
at The Street - Tue Feb 03, 5:22AM CST
European stocks rise Tuesday as the new Greek government looks to be backing down from a confrontation with euro-area leaders over a debt write-down.
SAN: 7.18 (+0.13), BHP: 51.19 (+2.38), BP: 41.93 (+0.59)
Why This Big Bank Slashed Its High-Yield Dividend
Eric Volkman, The Motley Fool - Motley Fool - Wed Jan 28, 9:32AM CST
Two words no investor ever wants to hear are "dividend cut." That's especially true when the cutter reduces its payout by two-thirds in one fell swoop. That's what happened earlier this month when sprawling Europe-based financial group Banco...
SAN: 7.18 (+0.13), C: 51.20 (+0.31)
Regeneron and Sanofi Announce Praluent(TM) (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
PR Newswire - Mon Jan 26, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for PraluentTM (alirocumab). Under the Prescription Drug User Fee Act (PDUFA), the goal for a priority review is six months, for a target action date of July 24, 2015. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
GE Q4 Operating Earnings Beat on Sustained Industrial Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 9:13AM CST
Sustained focus on core industrial business enabled General Electric Company (GE) to report strong fourth quarter 2014 results, with solid industrial segment profit growth and margin expansion.
SAN: 7.18 (+0.13), GE: 25.15 (+0.26), FSS: 15.75 (+0.09)
There's A Lot Of Value In The Information Technology Sector: The S&P 500 2015: Part 3
Chuck Carnevale - at Seeking Alpha - Thu Jan 22, 1:56PM CST
FB: 75.74 (-0.49), STX: 61.83 (+0.67), GOOG: 549.01 (+6.08), HPQ: 38.56 (+0.19), SAN: 7.18 (+0.13), FSLR: 48.84 (-0.58), IOT: 6.43 (+0.05), QCOM: 70.88 (+0.49), EMC: 27.99 (+0.12), GOOGL: 551.16 (+5.15), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03), MA: 87.14 (-0.38)
Spain: Unemployment stuck at 23.7 percent in Q4
AP - Thu Jan 22, 10:28AM CST
MADRID (AP) — Spain's unemployment rate remained stuck at 23.7 percent in the fourth quarter ending in December compared with the previous three-month period, marking an end to a series of joblessness rate declines throughout 2014, the government's statistics agency said Thursday.
SAN: 7.18 (+0.13), SANW: 4.80 (+0.19)
Santander Holdings announces preferred stock dividend of USD0.45625 per depositary share
M2 - Thu Jan 22, 3:11AM CST
Santander Holdings USA Inc, the parent company of Santander Bank NA (NYSE:SAN), reported on Wednesday that its board of directors authorised a dividend of USD0.45625 per depositary share on its series C non-cumulative perpetual preferred stock (NYSE:SOVPRC).
SAN: 7.18 (+0.13)
European Commission Grants Marketing Authorization for Cerdelga(R) (eliglustat), Genzyme's Oral Therapy for Gaucher Disease Type 1
Business Wire - Thu Jan 22, 12:00AM CST
Genzyme, a Sanofi company, announced today that the European Commission (EC) has granted marketing authorization for Cerdelga(R) (INN: eliglustat) capsules, a first line oral therapy for certain adults living with Gaucher disease type 1. A small number of adult patients who metabolize Cerdelga more quickly or at an undetermined rate, as detected by an established genetic laboratory test, will not be eligible for Cerdelga treatment. Cerdelga was approved by the U.S. Food and Drug Administration in August 2014, and is under review by other regulatory authorities around the world. It is expected that Cerdelga will be available commercially in EU countries beginning in 2015 and over the next few years.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
